Hiperhomocisteinemia moderada: Fisiopatología de la lesión endotelial e implicación clínica

Sangre

Volumn 43, Issue 1, 1998, Pages 47-54

  Falcón, Cristina R ^a   Carreras, Luis O ^a  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN FAVALORO   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

HOMOCYSTEINE; METHIONINE; VITAMIN;

BLOOD; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; DISORDERS OF AMINO ACID AND PROTEIN METABOLISM; GENETICS; HEART MUSCLE ISCHEMIA; HOMOCYSTINURIA; HOMOZYGOTE; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PERIPHERAL VASCULAR DISEASE; REVIEW; RISK FACTOR; THROMBOPHLEBITIS; VASCULAR ENDOTHELIUM; VITAMIN DEFICIENCY;

AMINO ACID METABOLISM, INBORN ERRORS; AVITAMINOSIS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; ENDOTHELIUM, VASCULAR; HOMOCYSTEINE; HOMOCYSTINURIA; HOMOZYGOTE; HUMANS; METHIONINE; MYOCARDIAL ISCHEMIA; PERIPHERAL VASCULAR DISEASES; RISK FACTORS; THROMBOPHLEBITIS; VITAMINS;

EID: 0031995957     PISSN: 00364355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (123)

1. Rees MM, Rodgers GM. Homocysteinemia: association of a metabolic disorder with vascular disease and thrombosis. Thromb Res 1993; 71: 337-359.
2. Mudd SH, Levy HL. Disorders of transsulfuration. In: Stanbury JB, Wyngarden JB, Fredrickson DS, Goldstein JL, Brown MS, eds. The metabolic basis of inherited disease. New York, NY: McGraw-Hill Book Co; 1983: 522-559.
3. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem 1993; 39: 1764-1779.
4. Andersson A, Brattström L, Israelsson B, Isaksson A, Hamfelt A, Hulberg B. Plasma homocysteine before and after methionine loading with regard to age, gender and menopausal status. Eur J Clin Invest 1992; 22: 79-87.
5. Brattström L, Lindgren A, Israelsson B, Andersson A, Hultberg B. Homocysteine and cysteine: determinants of plasma levels in middle-aged and elderly subjects. J Int Med 1994; 236: 633-641.
6. Lussier-Cacan S, Xhignesse M, Piolot A, Selhub J, Davignon J, Genest J. Plasma total homocysteine in healthy subjects: sex-specific relation with biological traits. Am J Clin Nutr 1996; 64: 87-93.
7. Refsum H, Nygȧrd O, Ku̇sle G, Ueland PM, Vollset SE. The Hordaland Homocysteine Study: the opposite tails odds ratios reveal differential effects of gender and intake of vitamin supplements at high and low plasma total homocysteine concentrations. J Nutr 1996; 126 (Suppl 4): 1244S-1248S.
8. Boers GH, Smals AG, Trijbels FJ, Leermakers AI, Kloppenborg PW. Unique efficiency of methionine metabolism in premenopausal women may protect against vascular disease in the reproductive years. J Clin Invest 1983; 72: 1971-1976.
9. Wouters MGAJ, Moorrees MThEC, Van Der Mooren MJ, Blom HJ, Boers GHJ, Schellekens LA et al. Plasma homocysteine and menopausal status. Eur J Clin Invest 1995; 25: 801-805.
10. Nordström M, Kjellstrom T. Age dependency of cystathionine beta-synthase activity in human fibroblasts in homocyst(e)inemia and atherosclerotic vascular disease. Atherosclerosis 1992; 94: 213-221.
11. Ubbink JB, Vermaak WJH, Delport R, van der Merwe A, Becker PJ, Potgieter H. Effective homocysteine metabolism may protect South African blacks against coronary heart disease. Am J Clin Nutr 1995; 62: 802-808.
12. Lolin YI, Sanderson JE, Cheng SK, Chan CF, Pang CP, Woo KS et al. Hyperhomocysteinaemia and premature coronary artery disease in the Chinese. Heart 1996; 76: 117-122.
13. Boers GHJ, Fowler B, Smals AGH, Trijbels FJM, Leermakers AI, Kleijer WJ et al. Improved identification of heterozygotes for homocystinuria due to cystathionine synthase deficiency by the combination of methionine loading and enzyme determination in cultured fibroblasts. Hum Genet 1985; 69: 164-169.
14. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996; 27: 517-527.
15. Wilcken B. Incidence of homocystinuria. Lancet 1975;Feb 1: 273-274.
16. Engbersen AMT, Franken DG, Boers GHJ, Stevens EMB, Trijbels FJM, Blom HJ. Thermolabil 5, 10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteienemia. Am J Hum Genet 1995; 56:142-150.
17. Kluijtmans LAJ, van den Heuvel LPWJ, Boers GHJ, Frosst P, Stevens EMB, van Oost BA et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylentetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996; 58: 35-41.
18. Deloughery TG, Evans A, Sadeghi A, McWilliams J, Henner WD, Taylor LM et al. Common mutation in methylenetetrahydrofolate reductase. Correlation with homocysteine metabolism and late-onset vascular disease. Circulation 1996; 94: 3074-3078.
19. Stampfer MJ, Willett WC. Homocysteine and marginal vitamin deficiency. The importance of adequate vitamin intake. JAMA 1993; 270: 2726-2727.
20. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intakes as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270: 2693-2698.
21. Ubbink JB, van der Merwe A, Delport R, Allen RH, Stabler SP, Riezler R et al. The effect of a subnormal vitamin B-6 status on homocysteine metabolism. J Clin Invest 1996; 98: 177-184.
22. Sumner AE, Chin MM, Abrahm JL, Berry GT, Gracely EJ, Allen RH et al. Elevated methylmalonic acid and total homocysteine levels show high prevalence of vitamin B 12 deficiency after gastric surgery. Ann Intern Med 1996; 124: 469-476.
23. Stabler SP, Lindenbaum J, Allen RH. The use of homocysteine and other metabolites in the specific diagnosis of vitamin B-12 deficiency. J Nutr 1996; 126 (Suppl 4): 1266S-1272S.
24. Refsum H, Ueland PM, Kvinnsland S. Acute and long-term effects of high-dose methotrexate treatment on homocysteine in plasma and urine. Cancer Res 1986; 46: 5385-5391.
25. Ermens AAM, Refsum H, Rupreht J, Spijkers LJM, Guttormsen AB, Lindemans J et al. Monitoring cobalamin inactivation during nitrous oxide anesthesia by determination of homocysteine and folate in plasma and urine. Clin Pharmacol Ther 1991; 49: 385-393.
26. Arnadottir M, Hultberg B, Vladov V, Nilsson-Ehle P, Thysell H. Hyperhomocysteinemia in cyclosporine-treated renal transplant recipients. Transplantation 1996; 61: 509-512.
27. Jensen MK, Ekelund S, Svendsen L. Folate and homocysteine status and haemolysis in patients treated with sulphasalazine for arthritis. Scand J Clin Lab Invest 1996; 56: 421-429.
28. Hultberg B, Agardh E, Andersson A, Brattström L, Isaksson A, Israelsson B et al. Increased levels of plasma homocysteine are associated with nephropathy, but not severe retinopathy in type 1 diabetes mellitus. Scand J Clin Lab Invest 1991; 51: 277-282.
29. Robinson K, Gupta A, Dennis V, Arheart K, Chaudhary D, Green R, et al. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996; 94: 2743-2748.
30. Brosnan JT, Hall B, Selhub J, Nadeau MR, Bostom AG. Renal metabolism of homocysteine in vivo. Biochem Soc Trans 1995; 23: 470S.
31. Harker LA, Ross R, Slichter J, Scott CR. Homocysteine-induced arteriosclerosis. J Clin Invest 1976; 58: 731-741.
32. Harker LA, Harlan JM, Ross R. Effect of sulfinpyrazone on homocysteine-induced endothelial injury and arteriosclerosis in baboons. Circ Res 1983; 53: 731-739.
33. McCully KS, Ragsdale BD. Production of arteriosclerosis by homocysteinemia. Am J Pathol 1970; 61: 1-8.
34. Donahue S, Sturman JA, Gaull G. Arteriosclerosis due to homocyst(e)inemia: failure to reproduce the model in weaning rabbits. Am J Pathol 1974; 77: 167-174.
35. Krishnaswamy K, Rao SB. Failure to produce atherosclerosis in Macaca radiata on a high-methionine, high-fat, pyridoxine-deficient diet. Atherosclerosis 1977; 27:253-258.
36. Reddy GSR, Wilcken DEL. Experimental homocysteinemia in pigs: comparison with studies in sixteen homocystinuric patients. Metabolism 1982; 31: 778-783.
37. Smolin LA, Crenshaw TD, Kurtycz D, Benevenga NJ. Homocyst(e)ine accumulation in pigs fed diets deficient in vitamin B6: relationship to atherosclerosis. J Nutr 1983; 113: 2122-2133.
38. Watanabe M, Osada J, Aratani Y, Kluckman K, Reddick R, Malinow MR et al. Mice deficient in cystathionine ß-synthase: Animal models for mild and severe homocyst(e)inemia. Proc Natl Acad Sci USA 1995; 92: 1585-1589.
39. Rolland PH, Friggi A, Barlatier A, Piquet P, Latrille V, Faye MM et al Hyperhomocysteinemia-induced vascular damage in the minipig. Captopril-hydrochlorothiazide combination prevents elastic alterations. Circulation 1995; 91: 1161-1174.
40. Lentz SR, Sobey CG, Piegors DJ, Bhopatkar MY, Faraci FM, Malinow MR et al. Vascular dysfunction in monkeys with diet-induced hyperthomocyst(e)inemia. J Clin Invest 1996; 98: 24-29.
41. Matthias D, Becker CH, Riezler R, Kindling PH. Homocysteine induced arteriosclerosis-like alterations of the aorta in normotensive and hypertensive rats following application of high doses of methionine. Atherosclerosis 1996; 122:201-216.
42. Lubec B, Arbeiter K, Hoeger H, Lubec G. Increased cyclin dependent kinase in aortic tissue of rats fed homocysteine. Thromb Haemost 1996; 75: 542-545.
43. Lubec B, Labudova O, Hoeger H, Muehl A, Fang-Kircher S, Marx M et al. Homocysteine increases cyclin-dependent kinase in aortic rat tissue. Circulation 1996;94:2620-2625.
44. Wall RT, Harlan JM, Harker LA, Striker GE. Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. Thromb Res 1980; 18:113-121.
45. De Groot PG, Willems C, Boers GHJ, Gonsalves MD, van Aken WG, van Mourik JA. Endothelial cell dysfunction in homocystinuria. Eur J Clin Invest 1983;13:405-410.
46. Blann AD. Endothelial cell damage and homocysteine. Atherosclerosis 1992; 94:89-91.
47. Hultberg B, Andersson A, Isaksson A. Metabolism of homocysteine, its relation to the other cellular thiols and its mechanism of cell damage in a cell culture (human histiocytic cell line U-937). Biochem Biophys Acta 1995; 1269: 6-12.
48. Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 1986; 77: 1370-1376.
49. Heinecke JW, Rosen H, Suzuki LA, Chait A. The role of sulfurcontaining amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J Biol Chem 1987; 262: 10098-10103.
50. Hirano K, Ogihara T, Miki M, Yasuda H, Tamai H, Kawamura N et al. Homocysteine induces iron-catalyzed lipid peroxidation of low-density lipoprotein that is prevented by alpha-tocopherol. Free Rad Res 1994; 21: 267-276.
51. Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein (a) to fibrin: a potential link between thrombosis, atherogenesis, and sulfhydril compound metabolism. Proc Natl Acad Sci USA 1992; 89: 10193-10197.
52. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M. Singel D et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993; 91: 308-318.
53. Graeber JE, Slott JH, Ulane RE, Schulman JD, Stuart MJ. Effect of homocysteine and homocystine on platelet and vascular arachidonic acid metabolism. Pediatr Res 1982; 16: 490-493.
54. Panganamala RV, Karpen CW, Morola AJ. Peroxide mediated effects of homocysteine on arterial prostacyclin synthesis. Prosta Leuko Med 1986; 22: 349-356.
55. Wang J, Dudman NPB, Wilcken DEL. Effects of homocysteine and related compounds on prostacyclin production by cultured human vascular endothelial cells. Thromb Haemost 1993; 70:1047-1052.
56. Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest 1986; 77:1909-1916.
57. Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood 1990; 75: 895-890.
58. Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 1991;88:1906-1914
59. Hayashi T, Honda G, Suzuki K. An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells. Blood 1992; 79: 2930-2936.
60. Nishinaga M, Ozawa T, Shimada K. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest 1993; 92: 1381-1386.
61. Hajjar KA. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 1993; 91: 2873-2879.
62. Lentz SR, Sadler JE. Homocysteine inhibits von Willebrand factor processing and secretion by preventing transport from the endoplasmic reticulum. Blood 1993;81:683-689.
63. Fryer RH, Wilson BD, Gubler DB, Fitzgerald LA, Rodgers GM. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb 1993; 13: 1327-1333.
64. Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 1994; 91: 6369-6373.
65. Tsai JC, Wang H, Perrella MA, Yoshizumi M, Sibinga NES, Tan LC et al. Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells. J Clin Invest 1996; 97: 146-153.
66. McDonald L, Bray C, Field C, Love F, Davies B. Homocystinuria, thrombosis, and the blood platelets. Lancet 1964; i: 745-746.
67. Harker LA, Scott CR. Platelets in homocystinuria. N Eng J Med 1977; 296: 818.
68. Hill-Zobel RL, Pyeritz RE, Scheffel U, Malpica O, Engin S, Camargo EE et al. Kinetics and distribution of 111 Indium-labeled platelets in patients with homocystinuria. N Eng J Med 1982; 307: 781-786.
69. Di Minno G, Davì G, Margaglione M, Cirillo F, Grandone E, Ciabattoni G et al. Abnormally high thromboxane biosynthesis in homozygous homocystinuria. J Clin Invest 1993; 92; 1400-1406.
70. Coppola A, Cirillo F, Soriente L, Pagano A, Madonna P, D'Angelo A et al. Raised in vivo thromboxane biosynthesis in obligate heterozygotes for cistathionine-ß-synthase deficiency (CBSD). Similarities and differences with the homozygous form. Haemostasis 1996; 26: 187.
71. Giannini MJ, Coleman M, Innerfield I. Antithrombin activity in homocystinuria. Lancet 1975, i: 1094.
72. Palareti G, Coccheri S. Lowered antithrombin III activity and other clotting changes in homocystinuria: effects of a pyridoxine-folate regimen. Haemostasis 1989; 19 (suppl 1): 24-28.
73. Bienvenu T, Chadefaux B, Ankri A, Leblond V, Coude M, Salehian B et al. Antithrombin III activity is not related to plasma homocysteine concentrations. Haemostasis 1991; 21: 65-67.
74. Wilcken DEL, Wilcken B. The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J Clin Invest 1976; 57: 1079-1082.
75. Wilcken DEL, Reddy SG, Gupta VJ. Homocysteinemia, ischemic heart disease, and the carrier state for homocystinuria. Metabolism 1983; 32: 363-370.
76. Boers GHJ, Smals AGH, Trijbels FJM, Fowler B, Bakkeren JAJM, Schoonderwaldt HC et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985; 313: 709-715.
77. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149-1155.
78. Malinow MR, Sexton G, Averbuch M, Grossman M, Wilson D, Upson B. Homocyst(e)inemia in daily practice: levels in coronary artery disease. Coronary Artery Disease 1990; 1: 215-220.
79. Genest JJ, McNamara JR, Upson B, Salem DN, Ordovas JM, Schaefer EJ et al. Prevalence of familial hyperhomocyst(e)inemia in men with premature coronary artery disease. Arterioscl Thromb 1991; 11: 1129-1136.
80. Wu LL, Wu J, Hunt SC, James BC, Vincent GM, Williams RR et al. Plasma homocyst(e)ine as a risk factor for early familial coronary artery disease. Clin Chem 1994; 40: 552-561.
81. Arnesen E, Refsum H, Bønaa KH, Ueland PM, Førde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995; 24:704-709.
82. Robinson K, Mayer EL, Miller DP, Green R, van Lente F, Gupta A et al. Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. Circulation 1995; 92: 2825-2830.
83. Morrison HI, Schaubel D, Desmeules M, Wigle DT. Serum folate and risk of fatal coronary heart disease. JAMA 1996; 275: 1893-1896.
84. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992; 268: 877-881.
85. Arnesen E, Refsum H, Bønaa KH, Ueland PM, Førde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995; 24:704-709.
86. Alfthan G, Pekkanen J, Jauhiainen M, Pitkanieml J, Karvonen M, Tuomilehto J, et al. Relation of serum homocysteine and lipoprotein (a) concentrations to atherosclerotic disease in a prospective Finish population based study. Atherosclerosis 1994; 106: 9-19.
87. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-1057.
88. Kang SS, Wong PWK, Susmano A, Sora J, Norusis M, Ruggie N. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet 1991; 48: 536-545.
89. Ma J, Stampfer MJ, Hennekens CH, Frosst P, Selhub J, Horsford J et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation 1996;94:2410-2416.
90. Gallagher PM, Meleady R, Shields DC, Tan KS, McMaster D, Rozen R et al. Homocysteine and risk of premature coronary heart disease. Evidenceforacommongene mutation. Circulation 1996;94:2154-2158.
91. Wilcken DEL, Wang XL, Sim AS, McCredie M. Distribution in healthy and coronary populations of the methylenetetrahydrofolate reductase (MTHFR) C677T mutation. Arterioscler Thromb Vasc Biol 1996; 16: 878-882.
92. Schmitz C, Lindpaintner K, Verhoef P, Gaziano JM, Buring J. Genetic polymorphism of methylenetetrahydrofolate reductase and myocardial infarction. A case control study. Circulation 1996; 94: 1812-1814.
93. van Bockxmeer FM, Mamotte CDS, Vasikaran SD, Taylor RR. Methylenetetrahydrofolate reductase gene and coronary artery disease. Circulation 1997; 95: 21-23.
94. Brattström LE, Hardebo JE, Hultberg BL. Moderate homocysteinemia- A possible risk factor for arteriosclerotic cerebrovascular disease. Stroke 1984; 15:1012-1016.
95. Coull BM, Malinow MR, Beamer N, Sexton G, Nordt F, de Garmo P. Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke. Stroke 1990; 21: 572-576.
96. Brattström L, Lindgren A, Israelsson B, Malinow MR, Norrving B, Upson B et al. Hyperhomocysteinaemia in stroke: prevalence, cause and relationships to type of stroke and stroke type factors. Eur J Clin Invest 1992; 22: 214-221.
97. Andersson A, Lindgren A, Hultberg B. Effect of thiol oxidation and thiol export from erythocytes on determination of redox status of homocysteine and other thiols in plasma from healthy subjects and patients with cerebral infarction. Clin Chem 1995; 41: 361-366.
98. Lindgren A, Brattström L, Norrving B, Hultberg B, Andersson A, Johansson BB. Plasma homocysteine in the acute and convalescent phases after stroke. Stroke 1995; 26: 795-800.
99. Egerton W, Silberberg J, Crooks R, Ray C, Xie L, Dudman N. Serial measures of plasma homocyst(e)ine after acute myocardial infarction. Am J Cardiol 1996;77:759-761.
100. Verhoef P, Hennekens CH, Malinow MR, Kok FJ, Willett WC, Stampfer MJ. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke 1994; 25: 1924-1930.
101. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995; 346:1395-1398.
102. Petri M, Roubenoff R, Dallal GE, Nadeau J, Selhub J, Rosenberg IR. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996; 348: 1120-1124.
103. Rubba P, Mercuri M, Faccenda F, Iannuzzi A, Irace C, Strisciuglio P et al. Premature carotid atherosclerosis: does it occur in both familial hypercholesterolemia and homocystinuria? Ultrasound assessment of arterial intima-media thickness and blood flow velocity. Stroke 1994; 25: 943-950.
104. Malinow MR, Nieto FJ, Szklo M, Chambless LE, Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The atherosclerosis risk in communities study. Circulation 1993; 87: 1107-1113.
105. Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PWF, Belanger AJ et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995; 332:286-291.
106. Malinow MR, Kang SS, Taylor LM, Wong PWK, Coull B, Inahara T et al. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circulation 1989; 79: 1180-1188.
107. Taylor LM, DeFrang RD, Harris J, Porter JM. The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease. J Vasc Surgery 1991; 13: 128-136.
108. Mölgaard J, Malinow MR, Lassvik C, Holm AC, Upson B, Olsson AG. Hyperhomocyst(e)inaemia: an independent risk factor for intermittent claudication. J Int Med 1992; 231: 273-279.
109. Aronson DC, Onkenhout W, Raben AMTJ, Oudenhoven LFIJ, Brommer EJP, van Bockel JH. Impaired homocysteine metabolism: a risk factor in young adults with atherosclerotic arterial occlusive disease of the leg. Br J Surgery 1994; 81: 1114-1118.
110. Mansoor MA, Bergmark C, Svardal AM, Lonning PE, Ueland PM. Redox status and protein binding of plasma homocysteine and other aminothiols in patients with early-onset peripheral vascular disease. Arterioscler Thromb Vasc Biol 1995;15:232-240.
111. van den Berg M, Stehouwer CDA, Bierdrager E, Rauwerda JA. Plasma homocysteine and severity of atherosclerosis in young patients with lower-limb atherosclerotic disease. Aterioscler Thromb Vasc Biol 1996; 16: 165-171.
112. Brattström L, Tengborn L, Lagerstedt C, Israelsson B, Hultberg B. Plasma homocysteine in venous thromboembolism. Haemostasis 1991; 21: 51-57.
113. Bienvenu T, Ankri A, Chadefaux B, Kamoun P. Dosage de l'homocystéine plasmatique dans l'exploration des thromboses du sujet jeune. La Presse Médicale 1991; 20: 985-988.
114. Falcon CR, Cattaneo M, Panzeri D, Martinelli I, Mannucci PM. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb 1994; 14: 1080-1083.
115. Fermo I, Vigano D'Angelo S, Paroni R, Mazzola G, Calori G, D'Angelo A. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med 1995; 123: 747-753.
116. den Heijer M, Blom HJ, Gerrits WBJ, Rosendaal FR, Wijermans PW, Bos GM. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet 1995; 345: 882-885.
117. den Heijer M, Koster T, Blom HJ, Bos GMJ, Briët E, Reitsma PH et al Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334: 759-762.
118. Simioni P, Prandoni P, Burlina A, Tormene D, Sardella C, Ferrari V et al. Hyperhomocysteinemia and deep-vein thrombosis. A case control study. Thromb Haemost 1996; 76: 883-886.
119. Wilcken DEL, Wilcken B, Dudman NPB, Tyrrell PA. Homocystinuria- the effects of betaine in the treatment of patients not responsive to pyridoxine. N Eng J Med 1983; 309: 448-453.
120. Brattström L. Vitamins as homocysteine-lowering agents. J Nutr 1996; 126: 1276S-1280S.
121. Dudman NPB, Wilcken DEL, Wang J, Lynch JF, Macey D, Lundberg P. Disordered methionine/homocysteine metabolism in premature vascular disease. Its occurrence, cofactor therapy, and enzymology. Arterioscler Thromb 1993; 13: 1253-1260.
122. Franken DG, Boers GHJ, Blom HJ, Trijbels FJM, Kloppenborg PWC. Treatment of mild hyperhomocsyteinemia in vascular disease patients. Arterioscler Thromb 1994;14: 465-470.
123. van den Berg M, Franken DG, Boers GHJ, Blom HK, Jakobs C, Stehouwer CDA et al. Combined vitamin B6 plus folic acid therapy in young patients with arteriosclerosis and hyperhomocysteinemia. J Vase Surg 1994; 20: 933-940.